Posted by Michael Wonder on 20 May 2021
FDA approves nivolumab for resected oesophageal or GEJ cancer
20 May 2021 - Today the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for patients with completely resected oesophageal or gastro-oesophageal junction cancer with residual pathologic disease who have received neo-adjuvant chemoradiotherapy.
Efficacy was evaluated in CHECKMATE-577, a randomized, multicenter, double-blind trial in 794 patients with completely resected (negative margins) oesophageal or gastro-oesophageal junction cancers who had residual pathologic disease following concurrent chemoradiotherapy.
